Claudio Rumazza

Health is the level of functional or metabolic efficiency of a living organism. In humans it is the ability of individuals or communities to adapt and self-manage when facing physical, mental or social challenges.

Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of Aortic Stenosis. The company's proprietary technology is based on delivering mechanical impact for creating scoring lines in valve calcification, without injuring the surrounding soft tissue. This treatment, which only takes several seconds, is intended to increase the valve effective orifice area without the need to replace the valve.

Angiodroid SpA is an Italian innovative Company that projects and trades solutions for the medical market. Angiodroid® The CO2 Injector is our main product. It is a Carbon Dioxide (CO2) Injector for Interventional Radiology procedures and represents the perfect solution for the treatment of patients with: • Contrast Induced Nephropathy (CIN) risk • Diabetic Disease • Renal Failure • Intolerance to Iodinated contrast media The use of CO2 in Peripheral Angiography has been common practice for many decades. To date, however, it has not the proper success due to the lack of advanced technology which could support operators during the procedures. Until now, the market solution was the use of manual injection kits (that means no procedural repeatability, no control of injection pressure and air contamination risk). Angiodroid® The CO2 Injector, whose main fields of application are Interventional Radiology & Vascular Surgery, is the perfect solution to all these problems and is the only injector: • 100 % automatic • 100 % safe • 100 % digital • 100 % user friendly More info at www.angiodroid.com

-

Health is the level of functional or metabolic efficiency of a living organism. In humans it is the ability of individuals or communities to adapt and self-manage when facing physical, mental or social challenges.

Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of Aortic Stenosis. The company's proprietary technology is based on delivering mechanical impact for creating scoring lines in valve calcification, without injuring the surrounding soft tissue. This treatment, which only takes several seconds, is intended to increase the valve effective orifice area without the need to replace the valve.

Angiodroid SpA is an Italian innovative Company that projects and trades solutions for the medical market. Angiodroid® The CO2 Injector is our main product. It is a Carbon Dioxide (CO2) Injector for Interventional Radiology procedures and represents the perfect solution for the treatment of patients with: • Contrast Induced Nephropathy (CIN) risk • Diabetic Disease • Renal Failure • Intolerance to Iodinated contrast media The use of CO2 in Peripheral Angiography has been common practice for many decades. To date, however, it has not the proper success due to the lack of advanced technology which could support operators during the procedures. Until now, the market solution was the use of manual injection kits (that means no procedural repeatability, no control of injection pressure and air contamination risk). Angiodroid® The CO2 Injector, whose main fields of application are Interventional Radiology & Vascular Surgery, is the perfect solution to all these problems and is the only injector: • 100 % automatic • 100 % safe • 100 % digital • 100 % user friendly More info at www.angiodroid.com

We are investors in companies that make the difference. We trust in great entrepreneurs, we partner with hard-working visionaries. Innogest is a Venture Capital firm focused on seed and early stage ventures, with more than € 200 milion of capital under management. We have over 100 years of cumulative professional experience in the digital and the healthcare fields. Innogest invests in high potential companies through a direct share in their equity and pays special attention to market potential and size. Innogest leverages its extensive network of contacts, working alongside its partners through its offices in Turin, Milan and San Francisco. Our mission is to generate high-level returns for our investors by turning entrepreneurship and technology into fast-growing and successful companies.